Compare Cadila Healthcare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs SUN PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE SUN PHARMA CADILA HEALTHCARE/
SUN PHARMA
 
P/E (TTM) x 34.9 86.8 40.2% View Chart
P/BV x 6.1 3.7 165.2% View Chart
Dividend Yield % 0.6 0.6 98.3%  

Financials

 CADILA HEALTHCARE   SUN PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
SUN PHARMA
Mar-20
CADILA HEALTHCARE/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs352484 72.8%   
Low Rs207315 65.5%   
Sales per share (Unadj.) Rs139.2136.9 101.7%  
Earnings per share (Unadj.) Rs11.817.5 67.4%  
Cash flow per share (Unadj.) Rs18.626.0 71.4%  
Dividends per share (Unadj.) Rs3.504.00 87.5%  
Dividend yield (eoy) %1.31.0 125.2%  
Book value per share (Unadj.) Rs101.4188.7 53.7%  
Shares outstanding (eoy) m1,023.742,399.26 42.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.02.9 68.7%   
Avg P/E ratio x23.722.9 103.7%  
P/CF ratio (eoy) x15.015.4 97.9%  
Price / Book Value ratio x2.82.1 130.1%  
Dividend payout %29.822.9 129.8%   
Avg Mkt Cap Rs m286,033958,864 29.8%   
No. of employees `00013.417.8 75.5%   
Total wages/salary Rs m24,14563,624 37.9%   
Avg. sales/employee Rs Th10,632.718,490.6 57.5%   
Avg. wages/employee Rs Th1,801.23,582.6 50.3%   
Avg. net profit/employee Rs Th898.52,357.6 38.1%   
INCOME DATA
Net Sales Rs m142,531328,375 43.4%  
Other income Rs m1,1396,360 17.9%   
Total revenues Rs m143,670334,735 42.9%   
Gross profit Rs m24,19869,898 34.6%  
Depreciation Rs m6,96520,528 33.9%   
Interest Rs m3,4183,027 112.9%   
Profit before tax Rs m14,95452,702 28.4%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m3,1988,228 38.9%   
Profit after tax Rs m12,04441,868 28.8%  
Gross profit margin %17.021.3 79.8%  
Effective tax rate %21.415.6 137.0%   
Net profit margin %8.512.8 66.3%  
BALANCE SHEET DATA
Current assets Rs m87,154316,542 27.5%   
Current liabilities Rs m82,694157,064 52.6%   
Net working cap to sales %3.148.6 6.4%  
Current ratio x1.12.0 52.3%  
Inventory Days Days7188 81.6%  
Debtors Days Days94105 89.6%  
Net fixed assets Rs m133,236243,102 54.8%   
Share capital Rs m1,0242,399 42.7%   
"Free" reserves Rs m102,733450,245 22.8%   
Net worth Rs m103,757452,645 22.9%   
Long term debt Rs m32,14620,289 158.4%   
Total assets Rs m236,866682,525 34.7%  
Interest coverage x5.418.4 29.2%   
Debt to equity ratio x0.30 691.2%  
Sales to assets ratio x0.60.5 125.1%   
Return on assets %6.56.6 99.2%  
Return on equity %11.69.2 125.5%  
Return on capital %13.711.2 122.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,75274,219 71.1%   
Fx outflow Rs m14,50427,964 51.9%   
Net fx Rs m38,24846,255 82.7%   
CASH FLOW
From Operations Rs m25,05465,548 38.2%  
From Investments Rs m-10,123-25,888 39.1%  
From Financial Activity Rs m-10,942-57,151 19.1%  
Net Cashflow Rs m3,989-13,857 -28.8%  

Share Holding

Indian Promoters % 74.8 63.7 117.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 5.1 161.8%  
FIIs % 5.9 23.0 25.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 8.3 132.5%  
Shareholders   44,069 133,026 33.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   SUVEN LIFE SCIENCES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  NEULAND LABS  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 350 Points Higher; Dr Reddy's Lab & Tata Steel Top Gainers(09:30 am)

Asian stock markets rose today amid speculation that interest rates will remain low due to receding inflationary pressure.

Related Views on News

AUROBINDO PHARMA at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)

May 10, 2021 | Updated on May 10, 2021

AUROBINDO PHARMA share price has hit a 52-week high. It is presently trading at Rs 1,047. BSE 500 Index is up by 0.7% at 20,165. Within the BSE 500, AUROBINDO PHARMA (up 2.4%) and GMDC (up 16.0%) are among the top gainers, while top losers are CHOLAMANDALAM INVEST and COFORGE.

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


May 10, 2021 11:20 AM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS